Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Our e-services for applications, projects and assessments close on Thursday 25 April at 4:30pm because of system upgrades. We expect to open them again on Friday 26 April at 8am the latest.

E!10668 eBIONERVE: Personalized nerve grafts for treating human nerve injuries, NovaHep AB

Reference number
Coordinator VERIGRAFT AB
Funding from Vinnova SEK 4 690 600
Project duration September 2016 - April 2020
Status Completed
Venture Eurostars

Purpose and goal

There is a significant medical need for peripheral nerve regeneration, and eBionerve wants to develop a potential solution. The overall purpose of the project has been to make this new and unique technology as ready as possible for upcoming clinical trials and market approval. Process development, large animal studies, preparation for GMP production and preparation of regulatory documents are among the most important goals that have been successfully achieved. In other words, our project results lead to entirely new medical and commercial opportunities for the future.

Expected results and effects

The project has now taken a first-generation promising product candidate through a series of important preclinical and regulatory development steps. The single most important result is positive in vivo data in a relevant disease model in large animals. At the same time, knowledge and expertise in this field has been built up and important partnerships and networks have been started. This platform will be very valuable and will serve as a basis for continued research and development. This gives Europe´s industry a prominent role in one of Life Science´s most interesting future areas.

Planned approach and implementation

eBionerve is a multi-task project where the partners have collectively performed as many key-steps as possible on the way from promising in vitro data to a complete set of preclinical activities, all in order to make the technology ready for commercial-scale up and clinical trials in the years to come. The commercial partner VERIGRAFT has covered process development and all documentary and commercial tasks, while the academic partner and subcontractors have made various in vivo disease models possible. In focus for the collaboration has been to pave the way a first product-candidate.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 1 May 2020

Reference number 2016-03675

Page statistics